March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD
The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome
Including sources of monounsaturated fat alongside protein and fibre may therefore help support appetite regulation and metabolic health
Products designed for fasting or low-carb diets often have the right balance
Hypoglycemia Hypoglycemia (low blood sugar) can occur with retatrutide, especially when you use the medication with other diabetes medications like insulin, sulfonylureas, or metformin
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin
